Patient characteristics and diagnostic evaluation in a management programme of Chronic Obstructive Pulmonary Disease (COPD) in Bogota (2640m), Colombia

Caracterización epidemiológica de una población de pacientes del programa «manejo integral de la enfermedad pulmonar obstructiva crónica» de la EPS Sanitas en Bogotá

Published 2008-03-01

Open | Download
PDF (Spanish) FLIP
Issue
Vol. 20 No. 1 (2008)
Section
Research article
How to Cite
Patient characteristics and diagnostic evaluation in a management programme of Chronic Obstructive Pulmonary Disease (COPD) in Bogota (2640m), Colombia.
rev. colomb. neumol. [Internet]. 2008 Mar. 1 [cited 2024 Nov. 24];20(1):3-9.
DOI
license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo  los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Andrés Caballero
Director científico Clínica Reina Sofía (CRS)
    María del Rocío Gordillo
    Jefe departamento Terapia CRS
      Luz D. Ardila
      Fisioterapeuta programa Toberín
        Milciades Ibáñez
        Bioestadístico Instituto de investigación Unisanitas
          Andrés Álvarez
          Neumólogo programa Toberín
            Show authors biography

            Objective: To describe the clinical and spirometric characteristics of patients admitted in a management program of the COPD in Bogotá.

            Material and method: A cross-sectional study. 756 patients with presumptive diagnosis of COPD were remitted to program, 408 (54%) were confirmed by spirometry, 57 of which were excluded. Information from 351 patients was collected on demographic, clinical and paraclinical characteristics and their relations with the COPD severity were described.

            Statistical Analysis: Descriptive statistics were used for characterizing patients. The parametric coefficient of Pearson and the non-parametric coefficient of Spearman were used under a level of significance of 1% (p<0.01).

            Results: COPD defined by a FEV1/FVC ratio< 70% post-bronchodilator was confirmed in 54% of the patients; only data from COPD patients were used for the analysis. Mean age was 72,8 ±9 and 61% were men; 9% were current smokers, 33% reported to have been exposed to wood smoke and 69% used the inhalators incorrectly. Approximately 68% of patients were not vaccinated for preventing pneumococcal infection and the 46% were not vaccinated against influenza.


            The average VEF1 was 1.285±517 liters. Direct and significant correlation was found between the VEF1 (%) with PaO2 saturation and the body mass index, and an inverse significant correlation was found between the VEF (%) and the PCO2, hematocrit and dyspnea index. No significant correlation was found between the VEF1 (%) and the quality of life (S. George) and the 6 minutes walk test.

            Conclusions: The 54% of patients remitted to program were adequately diagnosed. We found poor compliance with influenza and pneumococcal vaccination and inadequate use of inhaler devices among COPD. We stress the importance of spirometry as a basic tool to confirm the diagnosis of COPD and recommends different strategies such as educative programs to improve COPD management.

            Article visits 92 | PDF visits 48

            Downloads

            Download data is not yet available.
            1. Murray CJ, López AD. Global mortality, disability and the contribution of risk factors: global burden of disease study. Lancet 1997; 349:1436-1442
            2. World Health Organization. The World Health Report 2002 – reducing risks, promoting healthy life. Geneva, World Health Organization, 2002, available at www.who.int
            3. GOLD. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of Chronic Obstructive Lung Disease. Update 2005. www.goldcopd.com. Based on NIH/NHLBI/WHO workshop. Glo- bal Initiative for Chronic Obstructive Lung Disease. Publication number 2701, April 2001. Am J Respir Crit Care Med 2001; 163:1256-1276.
            4. Quintano JA. La enfermedad pulmonar obstructiva crónica: una asignatura pendiente en atención primaria para el siglo XXI. Semergen.2002; 28:11-4.
            5. Halbert R, Isonaka S, Geroge D, Iqbal A. Interpreting COPD Prevalence Estimates. What Is The Burden of Disease? CHEST 2003; 123: 1684-1692.
            6. Mannino David M, Epidemiology and Global Impact of Chronic Obstructive Pulmonary Disease. Seminars in Respiratory and critical Care Medicine 2005; 26: 204-210
            7. Caballero A, Torres C, Maldonado D, Jaramillo C, Guevara D Prevalencia de la enfermedad pulmonar obstructiva crónica en cinco ciudades colombianas. MEDISANITAS. Edición Especial: 2005. p. 8-27.
            8. Donaldson GH, Wedzicha JA. COPD exacerbations. 1. Epidemiology. Thorax 2006; 61:164-168
            9. Censo general 2005 en Colombia. Departamento Administrativo Nacional de Estadística (DANE)
            10. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932-46..
            11. Asociación Colombiana de Neumología y Cirugía de Tórax. En-fermedad pulmonar obstructiva crónica-EPOC. Diagnóstico y manejo integral. Recomendaciones. Rev Colomb Neumol 2003 ;15 (supl) S1-S34
            12. Casanova Macario C, I García-Talavera Martín y J.P. de Torres Tajés. La disnea en la EPOC. Arch Bronconeumol. 2005; 41(Supl 3):24-32.
            13. Fletcher CM. Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). Br Med1960; 2:1665.)
            14. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002:166; 111- 117
            15. Ferrer M, Alonso J, Prieto L, Plaza V, Monsó E, Marrades R, et al. Validity and reliability of the St. George’s Respiratory Questionnaire after adaptation to a different language and culture: the Spanish example. Eur Respir J 1996 ;9 :1160- 1167)
            16. Celli B, Cote C, Marin J, Casanova C, Montes de Oca M, Pinto V, Cabaral H. The Body-mass Index, Airflow Obstruction, Dyspnoea, and exercise Capacity Index. N Eng J Med 2004; 350: 1005-1012.
            17. Gonzáles M, Escalante H. Pacientes con enfermedad pulmonar obstructiva crónica de un programa de oxígeno domiciliario en Bogotá (2640m). Correlación entre la PaCO2 y la PaO2 con los valores de espirometría. Hospital Central Policía Nacional (HOCEN). Rev Colomb Neumol. 2001; 13:100-105
            18. Maldonado P, Peña C, Pinzón V, Aguilar P, Casas A. Caminata de seis minutos en pacientes con EPOC en Bogotá. Abstract. Rev Colomb Neumol. 2005; 17(3): 23
            19. De Miguel D, Izquierdo JL, Molina J, Rodríguez JM, De Lucas P, Gaspar G. Fiabilidad del diagnóstico de la EPOC en atención primaria y neumología en España. Factores predictivos. Arch Bronconeumol 2003; 39: 203- 208.
            20. R de Marco, S Accordini, I Cerveri, A Corsico. J Sunyer, F Neukirch, N Künzli, B Leynaert, C Janson, T Gislason, P Vermeire, S Svanes, J M Anto, P B, for the European Community. Respiratory Health Survey,(ECRHS) Study Group. Sn international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. THORAX 2004; 59:120-125.)
            21. Menezes AMB, Perez-Padilla R, Jardim JB, Muiño A, Lopez MV, Valdivia G, de Oca MM, Talamo C, Hallal PC, Victora CG. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005:366:1875-1881.
            22. Lacasse Y, Laforge J, Maltais F. Got a match? Home oxygen therapy in currents smokers Thorax 2006; 61:374-375),
            23. Pérez-Padilla R, Regalado J, Vadel S, Pare P, Chapela R, Samons R et al. Exposure to biomass smoke and chronic airway diseases in Mexican women. Am J Respir Crit Care Med 1996; 154:701- 706.
            24. Dennis RJ, Maldonado D, Norman S, Baena E, Martínez G. Woodsmoke exposure and risk for chronic obstructive airways disease among women. Chest 1996; 109: 115-119.
            25. Albalak R, Frisancho AR, Keeler GJ. Domestic biomass fuel combustion and chronic bronchitis in two rural Bolivian villages. Thorax 1999; 54:1004-8.
            26. Orozco-Levi M, Garcia-Aymerich J, Villar J, Ramírez-Sarmiento A, Antó JM, Gea J. Wood smoke exposure and risk for chronic obstructive pulmonary disease. Eur Respir J 2006; 27:542-6.)
            27. Horne SL, To T, Cockcroft DW. Ethnic differences in the prevalence of pulmonary airway obstruction among grain workers. Chest 1989; 95:992-996.
            28. Samet JM, Schrag SD, Howard SA, et al. Respiratory disease in a New Mexico population sample of Hispanic and non Hispanic whites. Am Rev Respir Dis 1982; 125:152-157.
            29. Kogevinas M, Anto JM, Tobias A et al. Respiratory symptoms, lung function and use of health services among unemployed young adults in Spain: Spanish group of the European Community Respiratory Health Survey. Eur Respir J 1998;11:1363-1368
            30. Viegi G,Carrozzi L, Di Pede F et al. Risk Factors for chronic obstructive pulmonary disease in a north Italian rural area. Eur J Epidemiol 1994;10:725-731.
            31. Weiss ST, Rosner B Campbell E et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med 1998;157:1770-1778.
            32. Gerardi DA, Lovett L, Benoit-Connors ML, Reardon JZ, ZuWallack RL, Variables related to increased mortality following outpatient pulmonary rehabilitation Eur Respir J 1996; 9:431-435.
            33. Landbo C, Presco HE, Lange P, Vertbo J, Almdal TP, Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160:1856-1861).
            34. Francia MD, Barbier D, Meje JL, Orejek.J. Tumor necrosis fac-tor-alfa levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994; 150; 1453-1455.
            35. Barreiro E, Gea J, Paqlacio J, Hussaim SNA. Expression of chronic oxido synthases (NOS) in chronic of COPD patients. Eur Respir J 2001; 18(Suppl33):S423.
            36. Coronell C, Orozco_levi M, Ramirez-Sarmiento A, Martinez- Llorens J, Broquetas J, gea J. Síndrome de bajo peso asociado a la EPOC en nuestro medio. Arch Bronconeumol 2002; 38: 580- 584.
            37. Eidd AA; Ionescu AA, Nixon Ls, Lewis –Jenkins V, Matthews SB, Griffiths TL et al. Inflammatory response and composition in chronic obstructive pulmonary disease Am J Respir Crit Care Med 2001; 164:1414-1418.
            38. Schols AMWJ, Soeters PB, Dingeman MC, Monstert R, Frantzen PJ, Wouters EFM. Prevalence and chronic characteristics of depletion in patients with stable COPD eligible for pulmonary rehabilitation Am J Respir Crit Care Med 1993; 147: 1151-1156.
            39. Poole PJ, Chacko E, Word-Baker RW, Cates CJ. Influenza Vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006 Jan 25;(1): CD002733.
            40. Miravitlles M, Mayordomo C, Artés M. et al. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice Respir Med 1999; 93: 173-179.
            41. De Blaquiere P, Christensen DB, Carter WB et al. Use and minsuse of the metered-dose inhaler by patients with chronic lung disease: a controlled ,randomized trial of two instruction methods. Am Rev Respir Dis 1989; 140: 910-916.
            42. Valoración de la técnica de utilización de los inhaladores de dosis medida. Evaluación pre y post instrucción en un grupo de pacientes asmáticos. Rev Colomb Neumol. 1995; Abstract 7(3): 170.
            43. Dolovich M, Ahrens R, Hess D, Anderson P, Dhand R, Rau J, Smaldone G, Guyatt G. Device selection and outcomes of Aero- sol Therapy: Evidence- Based Guidelines. CHEST 2005; 127:335- 371.
            44. Imfeld S, Bloch C, Weder W, and Russi E. The BODE Index After Lung Volume Reduction Surgery Correlates With Survival CHEST. 2006; 129:873-878.

            Information

            Journal history

            Keywords

            QR code

            Funding

            Support + Info: Here

             

             

            Directories and indexes

            Google Scholar profile

            Most read in the last 30 days

            Current Issue

            Sistema OJS 3.4.0.7 - Metabiblioteca |